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Children in Malawi receive bacille Calmette-Gue´rin (BCG) vaccination within the ﬁrst 3
days of life. Thus, we hypothesized that Malawian children infected with the human
immunodeﬁciency type 1 virus (HIV-1) might be particularly vulnerable to dissemina-
tion of the BCG Mycobacterium bovis strain with which they were vaccinated. Following
informed consent by parents, we studied children admitted to a Malawi general hospital
during the 1998 wet and dry seasons. Blood from cohorts of acutely ill children was
cultured for bacteria, including mycobacteria, and fungi, and tested for anti-HIV-1
antibodies. It was shown that non-typhi Salmonella and Escherichia coli were the pre-
dominant bloodstream pathogens during the wet and dry seasons, and that bloodstream
dissemination of the BCG M. bovis strain is uncommon in HIV-1-infected children who
receive the BCG vaccine.
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Recently published studies have documented that
Mycobacterium tuberculosis is a frequent cause of
bloodstream infections (BSIs) in febrile, adult inpa-
tients in Sub-Saharan Africa and is signiﬁcantly
associated with human immunodeﬁciency virus
type 1 (HIV-1) infection [1–3]. In contrast, all of the
published studies of BSI in pediatric populations
in these regions have focused solely on isolating
bacteria rather than mycobacteria or fungi [4–6]. In
consequence, the prevalence, epidemiology and
clinical features of M. tuberculosis BSIs in HIV-1-
infected pediatric patients in Sub-Saharan Africa
remain unknown.
In Malawi, the bacille Calmette-Gue´rin (BCG)
immunization program implemented by the Min-
istry of Health recommends that all newborn
infants receive BCG vaccination within the ﬁrst
3 days of life (Pasteur Me´rieux Connaught BCG
vaccine, derived from strain 1077 and containing
between 0.4 and 1.6 106 culturable particles per
newborn dose). Thus, we hypothesized that Mala-
wian HIV-1-infected pediatric patients might be
particularly vulnerable to M. tuberculosis BSI, as
was demonstrated in Malawian HIV-1-infected
adult patients [2,7], or prone to dissemination of
the BCG bacillus strain with which they were
vaccinated. Therefore, we conducted this pilot
study to: (1) estimate the frequency of bacteremia,
mycobacteremia or fungemia in an inpatient
pediatric population; and (2) ascertain whether
HIV-1-infected children who received the BCG
vaccination are at particular risk of acquiring M.
bovis BSI caused by dissemination of the BCG
strain. Approval for conduct of a pilot study
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was granted by the Malawian Health Sciences
Research Committee in the Malawi Ministry of
Health and by the Institutional Review Board at
the Centers for Disease Control and Prevention,
Atlanta, GA, USA.
The study was conducted at Lilongwe Central
Hospital (LCH), a 450-bed government regional
medical center in central Malawi that provides
services to a patient catchment area of approxi-
mately 230 000 citizens. We studied children
admitted to the LCH pediatric inpatient service
during each of the seasons in 1998. During the
wet season study period (22 March to 4 April
1998), consecutive, febrile (axillary temperature
37.5 8C on admission), BCG-vaccinated children
( 13 years) admitted to the LCH pediatric service
were evaluated on admission. We initially used
fever as the entry criterion for thewet season phase
of our study, because of its predictive value for
underlying sepsis in the adult patient population.
During the ﬁrst (i.e. the wet season) phase of our
study, however, we noted that there were signiﬁ-
cant numbers of children who were afebrile but
had other clinical features that suggested under-
lying sepsis. Thus, during the subsequent dry
season study period (28 July to 18 August 1998),
we modiﬁed the case deﬁnition to include all
acutely ill children ( 13 years) who were
admitted to the LCH pediatric inpatient service.
Patients were formally enrolled in the study
after informed consent was obtained from their
parents or guardians. For each patient at admis-
sion, basic clinical and demographic data were
recorded by one of the investigators. Next, each
patient’s skin was cleaned with 2% tincture of
iodine and 70% alcohol, and venous blood was
drawn for culture, blood count, HIV-1 testing, and
preparation of malaria smears. All parents and
guardians received HIV-1 pre- and post-test coun-
seling. HIV-1 test results were reported to the
pediatrician in charge of the child’s inpatient care.
For patients recruited during the wet season,
blood from a single venipuncture was cultured
using two blood culture systems: 3–5mL blood
was inoculated into a BACTEC MYCO/F LYTIC
(MFL; Becton Dickinson Microbiology Systems,
Cockeysville, MD, USA) blood culture vial, and
1.5mL was inoculated into a pediatric ISOLATOR
(Isolator) tube (Wampole Laboratories, Cranbury,
NJ, USA). The Isolator tube was processed accord-
ing to the manufacturer’s recommendations, and
the lyzed blood was cultured for mycobacteria on
Middlebrook 7H11 agar slants, as previously
described [2]. For the dry season phase of the
study, 3–5mL blood from a single venipuncture
was inoculated into a single MFL vial. Blood cul-
ture vials and agar slants were incubated aerobi-
cally at 35 8C. MFL blood culture vials were
examined for growth by using an ultraviolet lamp
to detect ﬂuorescence of the indicator at the bottom
of the vial [8]. This was performed daily during the
ﬁrst week, and then once weekly for a total of
8weeks or until growth was detected. Middleb-
rook agar slants were read macroscopically
weekly for 6weeks or until growth was observed.
All blood culture vials and organisms isolated at
the study site were transported to the Clinical
Microbiology Laboratory at Duke UniversityMed-
ical Center for further processing and conﬁrma-
tion. Thick blood smears were prepared from the
blood of each enrolled child, stained with a mod-
iﬁed Wright stain, and examined microscopically
for the presence of malaria parasites. Serum sam-
ples were assayed in batches using the SUDS HIV-
1 and -2 enzyme-linked immunosorbent assay
(ELISA) test kits (Murex Diagnostics Inc., Nor-
cross, GA, USA). Positive HIV-1 ELISA results
were veriﬁed in a second test before reporting to
the pediatricians in charge of patient care.
Eighty febrile children were enrolled during the
wet season phase; 44 (55%) weremale. Themedian
age was 2.5 years (range: 2weeks to 13 years); the
median body temperature was 38.4 8C (range:
37.5–40.0 8C); the median white cell blood count
was 7100 (range: 1000–40 900) white cells/mm3;
and the median hematocrit count was 25.6%
(range: 9.4–45.6%). All study patients had BCG
scars indicating previous vaccination. Fifteen
(19%) patients had positive malaria blood ﬁlms,
25 (31%) were seropositive for anti-HIV-1 anti-
body, and 12 (15%) had a BSI. Bloodstream patho-
gens recovered by the MFL vial included 11
isolates of bacteria (one Acinetobacter baumanii;
two Escherichia coli; six non-typhi Salmonella spp.;
one Salmonella typhi; one Staphylococcus aureus) and
one of M. avium complex.
During the dry season phase of the study, 128
acutely ill patients with BCG scarring were
enrolled; 67 (52%) were female. Their median
age was 2.0 years (range: 2.5months to 13 years);
the median body temperature was 37.7 8C (range:
33.9–41.0 8C); the median white cell blood count
was 12 200 (range: 1600–99 000) white cells/mm3;
and the median hematocrit count was 35.1%
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(range: 8.3–70%). Eight (6.3%) of these 128 patients
had positive malaria blood ﬁlms, 38 (29.7%) were
seropositive for anti-HIV-1 antibody, and 18
(14.1%) had a BSI. Of the 18 bloodstream patho-
gens recovered by the MFL vial, 15 were non-typhi
Salmonella spp. and three were E. coli.
No Streptococcus pneumoniae, fungi or M. tuber-
culosis strains were isolated from the bloodstream
of patients in either of the two patient populations.
For neither study population, was there a signiﬁ-
cant association between having a positive blood
culture and patient HIV-1 status. As expected, the
malaria parasitemia rate during the wet season
was signiﬁcantly higher than the dry season rate
(19% versus 6.3%, P< 0.01), and it almost certainly
accounts for the lower median hematocrit ob-
served during the wet season (25.6% versus 35.1%,
P< 0.001).
These preliminary data document a BSI rate of
approximately 15% in febrile or acutely ill pedia-
tric inpatients in aMalawi teaching hospital. More-
over, mycobacteria appear to be uncommon BSI
pathogens in both pediatric study populations,
despite a 30% HIV-1 seroprevalence rate and rela-
tively recent BCG vaccination. These ﬁndings are
in keeping with published data documenting that
the BCG vaccine is more likely to prevent disse-
minated forms of tuberculosis in children than
pulmonary tuberculosis in adolescents or adults
[9]. Other data have conﬁrmed that the risk of
disseminated BCG M. bovis is low among HIV-1-
infected adult patients who were given the BCG
vaccine in childhood [2,10].
BCG dissemination as deﬁned by a positive
blood culture for BCG M. bovis is a recognized
complication in immunosuppressed children who
have received the BCG vaccination [11]. Moreover,
published case reports have highlighted children
with advanced HIV-1 disease who developed dis-
seminated BCG infection that was detected by
blood cultures [12,13]. However, the ﬁrst study
to use blood cultures for the detection of dissemi-
nated mycobacteria in an African BCG-vaccinated
pediatric population was published only recently,
and demonstrated a paucity of mycobacterial BSI
[14]. Our preliminary data corroborate the ﬁnd-
ings of this study, that the acquisition of HIV-1
infection does not necessarily predispose BCG-
vaccinated pediatric patients to dissemination of
the live attenuated vaccine strain M. bovis BCG.
Because all the patients in our study had been
immunized with BCG, we were not able to make
any inferences as to the relative protection
afforded by being vaccinated with BCG. This pro-
tective effect could be assessed by prospectively
studying parallel populations of pediatric patients
with or without BCG vaccination. To date, how-
ever, no published studies have used mycobacter-
ial blood cultures to determine the protective effect
of BCG in reducing disseminated disease in chil-
dren in HIV-1-endemic regions or to delineate any
association between receiving the BCGvaccination
and dissemination of the M. bovis BCG strain.
Surprisingly, no S. pneumoniae bacteremia was
documented in our pediatric study population.
Previous research at LCH had shown that S. pneu-
moniae is a relatively common bloodstream patho-
gen in adult inpatients, particularly in those with
HIV-1 infection [2,7]. Moreover, the frequency of S.
pneumoniae BSI in these adult LCH inpatients var-
ied with the Malawi season: high in the dry season
and relatively less frequent in the wet [7]. The only
published study of bacteremia in Malawian chil-
drenwas conducted byWalsh et al. in the southern
part of the country. In that study, Enterobacteria-
ceae and S. pneumoniae accounted for two-thirds
and one-quarter of bacteremic episodes, respec-
tively [6]. The blood culture method used in our
study is very sensitive for bacterial growth, and
would have detected >90% S. pneumoniae BSIs in
our study patients [8]. Because our two pediatric
study cohorts represent snapshots of the Malawi
wet and dry seasons, the observed absence of S.
pneumoniae BSI in these patients may be an aberra-
tion due to geographic variation or differences in
sampling.
Published studies of BSI in pediatric popula-
tions in Sub-Saharan Africa have highlighted only
bacteremia [4–6] rather then mycobacteremia or
fungemia. There are several reasons for this. First,
culturing blood simultaneously for bacteria, myco-
bacteria, and fungi, using conventional methods,
often requires drawing >25mL of blood from
patients. Drawing such relatively large blood
volumes is unrealistic in infants or children, espe-
cially in those who are already immunocompro-
mised, malnourished, or severely anemic, as the
hematocrit measurements in our study show. Sec-
ond, for cultural reasons, parents may be reluctant
for their children to be obliged to provide the
seemingly large volumes of blood that are neces-
sary when culturing for bacteria, mycobacteria,
and fungi. Third, such volumes of blood may be
difﬁcult to obtain aseptically from pediatric popu-
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lations, especially those with small, fragile veins.
Fourth, many less developed countries do not
have the laboratory capacity, infrastructure or
skilled personnel required to provide a microbiol-
ogy service or to process additional mycobacterial
or fungal blood cultures. Fifth, the technician time,
laboratory equipment and materials required to
process multiple media and conduct microbiolo-
gical tests to identify various pathogens may
involve prohibitive or unsustainable costs.
In our study, we inoculated 3–5mL of blood into
each MFL vial. Such volumes of blood might seem
small when one considers that published recom-
mendations for obtaining blood cultures call for
two separate blood draws, each a minimum of
10mL [15,16]. However, we recently showed that
inoculation of just 5mL of blood from febrile
Malawian adults into one MFL vial gives a recov-
ery rate of 92% for both bacteria and mycobacteria
[17].
In summary, our preliminary data suggest that
in a region of HIV-1 endemicity in central Malawi,
bloodstream dissemination of M. tuberculosis and
the BCG M. bovis strain remains uncommon in
HIV-1-infected children who received the BCG
vaccine. Gram-negative organisms, particularly
non-typhi Salmonella spp. and E. coli, appear to
be the predominant bloodstream pathogens in
HIV-1-infected children in this region.
ACKNOWLEDGMENTS
We are indebted to the nursing and medical staffs
in the Department of Medicine and Pediatrics at
Lilongwe Central Hospital, the parents and guar-
dians who gave consent for their children to par-
ticipate in the study, the children themselves, and
the Malawi Ministry of Health and the United
States Agency for International Development,
Malawi, for facilitating the conduct of this study.
Becton Dickinson Microbiology Systems kindly
provided BACTEC MFL vials for this project.
REFERENCES
1. Archibald LK, den Dulk MO, Pallangyo KJ, Reller
LB. Fatal Mycobacterium tuberculosis bloodstream
infections in febrile hospitalized adults in Dar es
Salaam. Tanzania Clin Infect Dis 1998; 26: 290–6.
2. Archibald LK, McDonald LC, Nwanyanwu O et al.
A hospital-based prevalence survey of bloodstream
infections in febrile patients in Malawi: implications
for diagnosis and therapy. J Infect Dis 2000; 181:
1414–20.
3. Ssali FN, Kamya MR, Wabwire-Mangen F et al. A
prospective study of community-acquired blood-
stream infections among febrile adults admitted to
Mulago Hospital in Kampala, Uganda. J Acquir
Immune Defic Syndr Hum Retrovirol 1998; 19:
484–9.
4. Wolf BH, Ikeogu MO, Vos ET. Effect of nutritional
and HIV status on bacteraemia in Zimbabwean
children who died at home. Eur J Pediatr 1995; 154:
299–303.
5. Nathoo KJ, Chigonde S, Nhembe M, Ali MH,
Mason PR. Community-acquired bacteremia in
human immunodeficiency virus-infected children
in Harare. Zimbabwe Pediatr Infect Dis J 1996; 15:
1092–7.
6. Walsh AL, Phiri AJ, Graham SM, Molyneux EM,
Molyneux ME. Bacteremia in febrile Malawian
children: clinical and microbiologic features. Pediatr
Infect Dis J 2000; 19: 312–18.
7. Bell M, Archibald LK, Nwanyanwu O et al.
Seasonal variation in the etiology of bloodstream
infections in a febrile inpatient population in a
developing country. Int J Infect Dis 2001; 5: 63–9.
8. Archibald LK, McDonald LC, Addison RM et al.
Comparison of BACTEC MYCO/F LYTIC and
WAMPOLE ISOLATOR 10 (lysis-centrifugation)
systems for detection of bacteremia, mycobacter-
emia, and fungemia in a developing country. J Clin
Microbiol 2000; 38: 2994–7.
9. Cohn DL. Use of the Bacille Calmette-Gue´rin
vaccination for the prevention of tuberculosis:
renewed interest in an old vaccine. Am J Med Sci
1997; 313: 372–6.
10. Marsh BJ, von Reyn CF, Edwards J et al. The risks
and benefits of childhood Bacille Calmette-Guerin
immunization among adults with AIDS. Interna-
tional MAC study groups. AIDS 1997; 11: 669–72.
11. Talbot EA, Perkins MD, Silva SF, Frothingham R.
Disseminated Bacille Calmette-Guerin disease after
vaccination.: case report and review. Clin Infect Dis
1997; 24: 1139–46.
12. Rosenfeldt V, Paerregaard A, Valerius NH. Dis-
seminated infection with Bacillus Calmette-Guerin
in a child with advanced HIV disease. Scand J Infect
Dis 1997; 29: 526–7.
13. Raton JA, Pocheville I, Vicente JM et al. Dissemi-
nated bacillus Calmette-Guerin infection in an HIV-
infected child: a case with cutaneous lesions. Pediatr
Dermatol 1997; 14: 365–8.
14. Waddell RD, Lishimpi K, von Reyn CF et al.
Bacteremia due to Mycobacterium tuberculosis or
M. bovis, Bacille Calmette-Guerin (BCG) among
HIV- positive children and adults in Zambia.
Dartmouth/UCLMS/UNZA Collaborative Study
Group. AIDS 2001; 15: 55–60.
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 234–238
Concise Communication 237
15. Reller LB, McLowry JD, Murray PR. Cumitech 1A,
blood cultures II. Washington, DC: American Society
for Microbiology, 1982.
16. Washington JA. Blood cultures: issues and con-
troversies. Rev Infect Dis 1986; 8: 792–802.
17. Archibald LK, Dobbie H, Kazembe P et al. Utility of
paired BACTEC MYCO/F LYTIC blood culture
vials for the detection of bacteremia, mycobacter-
emia, and fungemia. J Clin Microbiol 2001; 39:
1960–2.
 2003 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 9, 234–238
238 Clinical Microbiology and Infection, Volume 9 Number 3, March 2003
